Inhibition of beta-1,3-glucan synthase and cell growth of Cryptococcus species by recombinant single-chain anti-idiotypic antibodies

The Journal of Antibiotics
Dakshnamurthy SelvakumarTadazumi Komiyama

Abstract

Recombinant single-chain fragment variable (scFv) anti-idiotypic antibodies were produced to represent the internal image of a HM-1 killer toxin, which is characterized by a wide spectrum of anti-fungal activity through inhibiting beta-1,3-glucan synthase (GS). We examined if scFv antibodies are active against Cryptococcus species, a human pathogen of increasing medical importance. The anti-cryptococcal activity of scFv antibodies and HM-1 were assessed by MIC analysis for C. neoformans IFM 40215 and C. albidus NBRC 0612 cells. The scFv antibodies had strong anti-cryptococcal activity in vitro with IC50 at 1.07 x 10(-7) to 2.60 x 10(-7) M for C. neoformans and C. albidus. Furthermore, the scFv antibodies potentially inhibited GS of C. neoformans with IC50 at 1.27 x 10(-7) to 2.27 x 10(-7) M. Both the anti-fungal and anti-GS activities of the scFv antibodies were markedly neutralized by the monoclonal antibody that neutralizes HM-1 killer toxin.

References

Jul 1, 1979·Journal of General Microbiology·J M BastideM Bastide
Mar 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E Anaissie
Apr 2, 1990·Carbohydrate Research·P G JamesE Reiss
Sep 21, 1989·The New England Journal of Medicine·S L Chuck, M A Sande
Jan 1, 1987·Methods in Enzymology·E Cabib, M S Kang
Mar 1, 1988·The Journal of Antibiotics·T YamamotoH Yamaguchi
Sep 29, 1986·The American Journal of Medicine·A T Masi, M B Yunus
Jan 1, 1985·Current Topics in Medical Mycology·F W Chandler
Sep 1, 1993·The Journal of Infection·F R KnightG C White
May 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W G Powderly
Apr 1, 1997·Dermatologic Clinics·P L MyskowskiR Ahkami
Jan 20, 2000·Antimicrobial Agents and Chemotherapy·J OnishiM B Kurtz
Feb 24, 2001·Medical Mycology·A Vecchiarelli
Sep 7, 2001·Annual Review of Microbiology·J A van Burik, P T Magee
Aug 6, 2002·Current Opinion in Microbiology·Jean-Paul Latgé, Richard Calderone

❮ Previous
Next ❯

Citations

Aug 31, 2006·Antimicrobial Agents and Chemotherapy·Dakshnamurthy SelvakumarTadazumi Komiyama
Sep 2, 2006·Biological & Pharmaceutical Bulletin·Dakshnamurthy SelvakumarTadazumi Komiyama
Nov 18, 2015·Immunological Investigations·Kausik Datta, Mawieh Hamad
Jul 22, 2014·Microbiology and Immunology·M Enamul KabirTadazumi Komiyama
Apr 27, 2019·Critical Reviews in Biotechnology·Ilaria MannazzuMaurizio Ciani
Sep 13, 2008·FEMS Microbiology Letters·Walter MaglianiLuciano Polonelli
May 18, 2011·Journal of Molecular Recognition : JMR·M Mamunur RahmanTadazumi Komiyama

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.